[go: up one dir, main page]

Vogel et al., 1972 - Google Patents

Physiological disposition of isoergine [from Argyreia nervosa (Burm. f.) Bojer Convolvulaceae] and its effect on the conditioned avoidance response in rats

Vogel et al., 1972

Document ID
3016913092718539104
Author
Vogel W
Carapellotti R
Evans B
Der Marderosian A
Publication year
Publication venue
Psychopharmacologia

External Links

Snippet

Physiological disposition of isoergine (d-isolysergamide, iso-LA) obtained from the seeds of Argyreia nervosa (Burm. f.) Bojer were determined in rat liver, brain and plasma. Method of determination involved the extraction of the drug from biological samples and quantitation of …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol, pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
    • A61K47/26—Carbohydrates, e.g. mono-, di-, oligosaccharides, nucleic acids, sugar alcohols, amino sugars; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters, glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Similar Documents

Publication Publication Date Title
DE69722580T2 (en) NEW STABLE LIQUID PARACETAMOL AGENTS AND METHOD FOR THE PRODUCTION THEREOF
DE69031033T2 (en) USE OF EICOSAPENTIC ACID FOR THE TREATMENT OF CACHEXIA
Koumaglo et al. Effects of three compounds extracted from Morinda lucida on Plasmodium falciparum
Gattu et al. Reversal of scopolamine-induced deficits in navigational memory performance by the seed oil of Celastrus paniculatus
CZ297951B6 (en) Stabilization process of naloxone
DE2822882A1 (en) SOLID PREPARATION COMPOSITION CONTAINING NIFEDIPINE, METHOD FOR PRODUCING AND USING IT
CA1163199A (en) Aqueous solution of nitroglycerin
McCORMICK et al. Cantharidin biosynthesis and function in meloid beetles
US5589513A (en) Pharmaceutical composition and process for the preparation thereof
DE60014916T2 (en) The use of a benzimidazole for the manufacture of a medicament for cancer prevention
Asencio et al. Biochemical and behavioral effects of boldine and glaucine on dopamine systems
BR0307974B1 (en) “LONG-ACTING PARASITIC COMPOSITION CONTAINING ONE SALICYLANILIDE COMPOUND, ONE POLYMERIC SPECIES AND AT LEAST ONE OTHER ANTIPARASITIC COMPOUND”
Karaman Antimalarial Atovaquone Prodrugs Based on Enzyme Models-Molecular Orbital Calculations Approach
DE4023774A1 (en) N-ACETYLCYSTEIN-CONTAINING ORAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION
DE69327153T2 (en) ANTI-HIV MEDICINE
Vogel et al. Physiological disposition of isoergine [from Argyreia nervosa (Burm. f.) Bojer Convolvulaceae] and its effect on the conditioned avoidance response in rats
Poklis et al. Xylazine in human tissues and fluids in a case of fatal drug abuse
EP1562613A1 (en) Nadh/nadph-containing compound
US5011853A (en) Compounds for treatment of cholinergic neurotoxins
Al-Zanbagi et al. Laboratory evaluation of the molluscicidal properties of some Saudi Arabian euphorbiales against Biomphalaria pfeifferi
Inamori et al. Mechanisms of insecticidal action of deoxypodophyllotoxin (Anthricin). I. Distribution of deoxypodophyllotoxin in tissues of the 5th instar larvae of silkworm, Bombyx mori Linne
Beleslin et al. The pharmacology of gross behavioural effects of cholinomimetic substances injected into the cerebral ventricles of unanaesthetized cats: evidence for central muscarinic mediation
Mak et al. Experimental chemotherapy of lymphatic filariasis. A review
Johnson et al. Chemical sympathectomy by guanidinium adrenergic neuron blocking agents
EP0106727B1 (en) Method of improving parenterally administerable physiologically active compositions by incorporating therein an epsilon-aminocaproic acid or tranexamic acid